Nektar Therapeutics clinical trials we track

Check company identity source

Phase 3 1 trial

Phase 2 / 3 1 trial

Phase 2 4 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Complete response (CR) rate at month 6 Description: The incidence of complete response by the Lugano Classification (Cheson et al, 2014) as determined by blinded independent central review (BICR) Time frame: At month 6 after the first infusion with study drug Measure: Event-free survival (EFS) Description: Event-free survival is defined as the time from randomization to the earliest date of disease progression by the Lugano Classification (Cheson et al, 2014) as determined by BICR, commencement of new lymphoma therapy, or death from any cause. Time frame: Up to 3 years after the first infusion with study drug. After: Measure: Complete Response (CR) Rate Description: The incidence of complete response by the Lugano Classification (Cheson et al, 2014) as determined by blinded independent central review (BICR) Time frame: At month 6.

Check registry source